Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Net Income: 2011-2024

Historic Net Income for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to -$625.6 million.

  • Ptc Therapeutics' Net Income rose 114.90% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $489.4 million, marking a year-over-year increase of 190.32%. This contributed to the annual value of -$625.6 million for FY2024, which is 12.53% up from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Net Income is -$625.6 million, which was up 12.53% from -$715.2 million recorded in FY2023.
  • Ptc Therapeutics' 5-year Net Income high stood at -$487.7 million for FY2020, and its period low was -$715.2 million during FY2023.
  • Its 3-year average for Net Income is -$634.5 million, with a median of -$625.6 million in 2024.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 93.86% in 2020, then rose by 12.53% in 2024.
  • Ptc Therapeutics' Net Income (Yearly) stood at -$487.7 million in 2020, then decreased by 7.42% to -$523.9 million in 2021, then declined by 7.40% to -$562.7 million in 2022, then fell by 27.12% to -$715.2 million in 2023, then climbed by 12.53% to -$625.6 million in 2024.